Form 4: OmniAb CLO Charles Berkman Vests RSUs and Sells for Taxes

OmniAb's Chief Legal Officer Charles Berkman acquired 13,542 shares through RSU vesting and sold 7,157 shares to cover mandatory tax obligations.

Summary

• Charles S. Berkman, Chief Legal Officer of OmniAb, Inc., reported a vesting of 13,542 Restricted Stock Units (RSUs) on April 7, 2026.
• Following the vesting, 7,157 shares were sold at a weighted average price of $1.49 to satisfy tax withholding obligations.
• The sale was a non-discretionary 'sell-to-cover' transaction mandated by the company's equity incentive plan.
• After these transactions, Berkman directly owns 399,085 shares of OmniAb common stock.
• Berkman still holds 111,042 unvested Restricted Stock Units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine event. While the executive sold shares, the non-discretionary nature of the 'sell-to-cover' for taxes means it does not signal a change in management's outlook on the company's value.

Positives

• The reporting person maintains a substantial direct ownership stake of 399,085 shares.
• The sale of shares was not a discretionary market exit but a required administrative action for tax purposes.
• The executive continues to hold 111,042 derivative securities, aligning long-term interests with shareholders.

Negatives

• The weighted average sale price of $1.49 per share reflects a relatively low valuation for the common stock at the time of the transaction.
• Over 50% of the vested shares (7,157 out of 13,542) were immediately sold to cover taxes, limiting the net increase in the executive's position.

Risks

• No specific business or operational risks are disclosed in this administrative ownership filing.

Future Outlook

The reporting person has 111,042 RSUs remaining, which will continue to vest according to the established schedule, ensuring ongoing executive participation in equity growth.

Management Comments

• The sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a sell-to-cover transaction and do not represent discretionary trades.

Industry Context

StockSavvy.ai notes that 'sell-to-cover' transactions are standard practice in the biotechnology and broader tech sectors to manage the immediate tax liability triggered by the vesting of equity awards without requiring the executive to use personal cash reserves.

Comparison to Industry Standards

• The use of RSUs with a three-year vesting period is consistent with standard executive compensation packages in the Russell 2000 biotech index.
• Mandatory sell-to-cover provisions are a common corporate governance feature used to simplify tax compliance for insiders.

Related Party Transactions

• The issuance of common stock upon vesting of RSUs is a compensation-related transaction between the company and its Chief Legal Officer.

Stakeholder Impact

• Shareholders see a minor increase in the total shares outstanding due to the vesting, though the executive's high level of retained ownership suggests continued alignment with shareholder interests.

Next Steps

• Continued annual vesting of the remaining 111,042 RSUs.

Key Dates

Recommendation

This filing is a routine disclosure of executive compensation activity and does not provide new material information regarding the company's operations or financial health that would warrant a change in investment stance.

Keywords

OmniAb, OABI, Insider Trading, Form 4, Charles Berkman, Restricted Stock Units, Sell-to-Cover, Executive Compensation, Biotechnology